• Innate Pharma SA's (NASDAQ: IPHA) futility interim analysis of the INTERLINK-1 Phase 3 study sponsored by AstraZeneca Plc (NASDAQ: AZN) did not meet a pre-defined threshold for efficacy.

• Based on this result and the recommendation of an Independent Data Monitoring Committee, AstraZeneca has informed Innate that the study will be discontinued.

• There were no new safety findings. AstraZeneca plans to share the data in due course.

• Related: Innate Pharma Says Chemo-Free Monalizumab Triplet Therapy Shows Preliminary Anti-Cancer Activity.

• The INTERLINK-1 study evaluated monalizumab in combination with cetuximab vs. cetuximab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.

• Monalizumab is being studied in a Phase 3 study sponsored by AstraZeneca, evaluating durvalumab in combination with monalizumab or AstraZeneca's oleclumab (anti-CD73) in patients with unresectable, Stage III non-small cell lung cancer.

• Price Action: IPHA shares are down 16.3% at $2.68 during the premarket session on the last check Monday.

See more from Benzinga

• AstraZeneca Drops Moderna-Partnered, Phase 2 Heart Disease Drug Candidate

• Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.